Deborah Proctor, MD

• Badr Al Bawardy
• David N. Assis
• Dhanpat Jain
• Guadalupe Garcia-Tsao
• James Dziura
• Jeffrey Pollak
• Jill Gaidos
• Karl Insogna
• Kenneth Hung
• Lawrence Young
• Malini Harigopal
• Marie Robert
• Peggy Myung
• Sangchoon Jeon
• Shawn Cowper
• Stuart Seropian
• Suguru Imaeda

Colitis, Ulcerative; Crohn Disease; Gastrointestinal Hemorrhage; Ileitis; Rectal Fistula; Telangiectasia, Hereditary Hemorrhagic; Global Health; Inflammatory Bowel Diseases

Global Health

• Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows.Al-Bawardy B, Malter L, Ehrlich A, Rieder F, Gaidos J, Proctor D, Windish D. Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows. Inflammatory Bowel Diseases 2023 PMID: 36810663, DOI: 10.1093/ibd/izad030.
• Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel diseaseSayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.
• S856 Predictors of Colectomy in Acute Severe Ulcerative ColitisSharma S, Li D, Levine L, Chaar A, McMillan C, Gaidos J, Proctor D, Al-Bawardy B. S856 Predictors of Colectomy in Acute Severe Ulcerative Colitis. The American Journal Of Gastroenterology 2022, 117: e618-e619. DOI: 10.14309/01.ajg.0000860064.59694.03.
• S863 Impact of Race on ANTI-TNF Immunogenicity in Patients with Inflammatory Bowel DiseaseNawaz A, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. S863 Impact of Race on ANTI-TNF Immunogenicity in Patients with Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2022, 117: e623-e624. DOI: 10.14309/01.ajg.0000860092.19979.d5.
• S862 Rates and Outcomes of Histologic Healing in Crohn's DiseaseMcMillan C, Levine L, Gaidos J, Proctor D, Al-Bawardy B, Jain D, Liang Y. S862 Rates and Outcomes of Histologic Healing in Crohn's Disease. The American Journal Of Gastroenterology 2022, 117: e622-e623. DOI: 10.14309/01.ajg.0000860088.69814.32.
• S875 Assessment of Inflammatory Bowel Disease Training Among Gastroenterology FellowsAl-Bawardy B, Malter L, Ehrlich A, Rieder F, Gaidos J, Proctor D, Windish D. S875 Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows. The American Journal Of Gastroenterology 2022, 117: e632-e632. DOI: 10.14309/01.ajg.0000860140.96667.49.
• 0573 Daytime and Nighttime Sleep and Symptoms of Depression and Anxiety in Adults with Inflammatory Bowel DiseaseConley S, Proctor D, Jeon S, Redeker N. 0573 Daytime and Nighttime Sleep and Symptoms of Depression and Anxiety in Adults with Inflammatory Bowel Disease. Sleep 2022, 45: a252-a252. DOI: 10.1093/sleep/zsac079.570.
• Mo1547: IMPACT OF EARLY VS DELAYED FLEXIBLE SIGMOIDOSCOPY ON OUTCOMES IN INPATIENT SEVERE ULCERATIVE COLITISSharma S, Levine L, McMillan C, Li D, Gaidos J, Proctor D, Bawardy B. Mo1547: IMPACT OF EARLY VS DELAYED FLEXIBLE SIGMOIDOSCOPY ON OUTCOMES IN INPATIENT SEVERE ULCERATIVE COLITIS. Gastroenterology 2022, 162: s-813. DOI: 10.1016/s0016-5085(22)61919-x.
• Tu1429: FREQUENCY AND CHARACTERISTICS OF NUTRITION ASSESSMENT IN HOSPITALIZED ULCERATIVE COLITIS PATIENTSLevine L, Sharma S, McMillan C, Li D, Gaidos J, Proctor D, Bawardy B. Tu1429: FREQUENCY AND CHARACTERISTICS OF NUTRITION ASSESSMENT IN HOSPITALIZED ULCERATIVE COLITIS PATIENTS. Gastroenterology 2022, 162: s-957. DOI: 10.1016/s0016-5085(22)62267-4.
• Gastrointestinal vascular malformations and neoplasms: arterial, venous, arteriovenous, and capillaryAl‐Bawardy B, Proctor D. Gastrointestinal vascular malformations and neoplasms: arterial, venous, arteriovenous, and capillary. 2022, 2293-2314. DOI: 10.1002/9781119600206.ch113.
• PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBDSayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD. Gastroenterology 2022, 162: s76. DOI: 10.1053/j.gastro.2021.12.161.
• OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA)Petrov J, Al-Bawardy B, Gaidos J, Proctor D. OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA). Gastroenterology 2022, 162: s75-s76. DOI: 10.1053/j.gastro.2021.12.160.
• IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASENawaz A, Glick L, Li D, Gaidos J, Proctor D, Al-Bawardy B. IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE. Gastroenterology 2022, 162: s107-s108. DOI: 10.1053/j.gastro.2021.12.221.
• PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBDSayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD. Inflammatory Bowel Diseases 2022, 28: s76-s76. DOI: 10.1093/ibd/izac015.124.
• OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA)Petrov J, Al-Bawardy B, Gaidos J, Proctor D. OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA). Inflammatory Bowel Diseases 2022, 28: s75-s76. DOI: 10.1093/ibd/izac015.123.
• IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASENawaz A, Glick L, Li D, Gaidos J, Proctor D, Al-Bawardy B. IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE. Inflammatory Bowel Diseases 2022, 28: s107-s108. DOI: 10.1093/ibd/izac015.174.
• Effect of obesity on vedolizumab response in inflammatory bowel diseaseLevine LJ, Gaidos JKJ, Proctor DD, Viana AV, Al-Bawardy B. Effect of obesity on vedolizumab response in inflammatory bowel disease. Annals Of Gastroenterology 2022, 35: 275-280. PMID: 35599926, PMCID: PMC9062841, DOI: 10.20524/aog.2022.0699.
• Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel diseaseNawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.
• The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination ServicesHussain N, Proctor D, Al-Bawardy B. The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services. Crohn's & Colitis 360 2021, 3: otab067-. DOI: 10.1093/crocol/otab067.
• The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination ServicesHussain N, Proctor D, Al-Bawardy B. The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services. Crohn's & Colitis 360 2021, 3: otab067-. PMID: 36777277, PMCID: PMC9802036, DOI: 10.1093/crocol/otab067.
• Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational StudiesTran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal Of Immunotherapy 2021, 44: 325-334. PMID: 34380976, DOI: 10.1097/cji.0000000000000383.
• Concise Commentary: Ill Preparation for Managing Liver Illness Among Incoming Medical ResidentsProctor DD. Concise Commentary: Ill Preparation for Managing Liver Illness Among Incoming Medical Residents. Digestive Diseases And Sciences 2021, 67: 2086-2086. PMID: 34365538, DOI: 10.1007/s10620-021-07195-9.
• DDS Profile: Deborah D. Proctor, MD.Proctor DD. DDS Profile: Deborah D. Proctor, MD. Digestive Diseases And Sciences 2021, 66: 2486-2488. PMID: 34215907, DOI: 10.1007/s10620-021-07102-2.
• DDS Perspective: Deborah D. Proctor, MD.Proctor DD. DDS Perspective: Deborah D. Proctor, MD. Digestive Diseases And Sciences 2021, 66: 2489-2492. PMID: 34215908, DOI: 10.1007/s10620-021-07103-1.
• AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021, 160: 2512-2556.e9. PMID: 34051985, PMCID: PMC8986997, DOI: 10.1053/j.gastro.2021.04.023.
• Su465 EFFECT OF OBESITY ON VEDOLIZUMAB RESPONSE IN INFLAMMATORY BOWEL DISEASELevine L, Gaidos J, Proctor D, Viana A, Bawardy B. Su465 EFFECT OF OBESITY ON VEDOLIZUMAB RESPONSE IN INFLAMMATORY BOWEL DISEASE. Gastroenterology 2021, 160: s-703-s-704. DOI: 10.1016/s0016-5085(21)02387-8.
• Sa566 OUTCOMES OF INFLAMMATORY BOWEL DISEASE WITH CONCOMITANT ADVANCED LIVER FIBROSIS AND CIRRHOSISLi M, Khan S, Gaidos J, Proctor D, Bawardy B. Sa566 OUTCOMES OF INFLAMMATORY BOWEL DISEASE WITH CONCOMITANT ADVANCED LIVER FIBROSIS AND CIRRHOSIS. Gastroenterology 2021, 160: s-554. DOI: 10.1016/s0016-5085(21)02022-9.
• Su464 PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASELevine L, Gaidos J, Proctor D, Bawardy B. Su464 PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE. Gastroenterology 2021, 160: s-703. DOI: 10.1016/s0016-5085(21)02386-6.
• Novel and Emerging Therapies for Inflammatory Bowel DiseaseAl-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Frontiers In Pharmacology 2021, 12: 651415. PMID: 33935763, PMCID: PMC8080036, DOI: 10.3389/fphar.2021.651415.
• THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSISLi M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Gastroenterology 2021, 160: s62. DOI: 10.1053/j.gastro.2021.01.159.
• THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSISLi M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Inflammatory Bowel Diseases 2021, 27: s45-s46. DOI: 10.1093/ibd/izaa347.110.
• Cutaneous Vasculitis After Ustekinumab Induction in Crohn's Disease.Chugh R, Proctor DD, Little A, Myung P, Cowper S, Imaeda S, Pashankar DS, Al-Bawardy B. Cutaneous Vasculitis After Ustekinumab Induction in Crohn's Disease. Inflammatory Bowel Diseases 2020, 27: e30-e31. PMID: 33179735, DOI: 10.1093/ibd/izaa285.
• The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study.Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.
• The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseasesDamsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. Journal Of Allergy And Clinical Immunology 2020, 147: 814-826. PMID: 33129886, DOI: 10.1016/j.jaci.2020.10.022.
• S0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel DiseaseHussain N, Proctor D, Ruggiero E, Al-Bawardy B. S0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2020, 115: s356-s356. DOI: 10.14309/01.ajg.0000704884.71749.ca.
• S0830 The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter StudyRamos G, Dimopoulos C, McDonald N, Janssens L, Hung K, Proctor D, Ruggiero E, Bruning D, Faubion W, Raffals L, Loftus E, Al-Bawardy B. S0830 The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. The American Journal Of Gastroenterology 2020, 115: s427-s428. DOI: 10.14309/01.ajg.0000705368.24314.98.
• The Feasibility of Measuring Sleep and Circadian Characteristics in Adults with Inflammatory Bowel DiseaseConley S, Proctor DD, Lehner V, Jeon S, Redeker NS. The Feasibility of Measuring Sleep and Circadian Characteristics in Adults with Inflammatory Bowel Disease. Western Journal Of Nursing Research 2020, 43: 53-59. PMID: 32517546, PMCID: PMC7704942, DOI: 10.1177/0193945920933926.
• Su1852 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASEDimopoulos C, Hung K, Proctor D, Ruggiero E, Al-Bawardy B. Su1852 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE. Gastroenterology 2020, 158: s-675. DOI: 10.1016/s0016-5085(20)32379-9.
• Sleep Characteristics and Rest–Activity Rhythms Are Associated with Gastrointestinal Symptoms Among Adults with Inflammatory Bowel DiseaseConley S, Jeon S, Lehner V, Proctor DD, Redeker NS. Sleep Characteristics and Rest–Activity Rhythms Are Associated with Gastrointestinal Symptoms Among Adults with Inflammatory Bowel Disease. Digestive Diseases And Sciences 2020, 66: 181-189. PMID: 32193859, PMCID: PMC8162988, DOI: 10.1007/s10620-020-06213-6.
• 23 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASEDimopoulos C, Hung K, Proctor D, Ruggiero E, Al-Bawardy B. 23 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE. Gastroenterology 2020, 158: s32-s33. DOI: 10.1053/j.gastro.2019.11.107.
• P099 LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN'S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEWChugh R, Proctor D, Little A, Myung P, Imaeda S, Al-Bawardy B. P099 LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN'S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEW. Gastroenterology 2020, 158: s3. DOI: 10.1053/j.gastro.2019.11.046.
• 23 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASEDimopoulos C, Hung K, Proctor D, Ruggiero E, Al-Bawardy B. 23 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE. Inflammatory Bowel Diseases 2020, 26: s19-s20. DOI: 10.1093/ibd/zaa010.047.
• P099 LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN’S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEWChugh R, Proctor D, Little A, Myung P, Imaeda S, Al-Bawardy B. P099 LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN’S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEW. Inflammatory Bowel Diseases 2020, 26: s2-s2. DOI: 10.1093/ibd/zaa010.004.
• 0636 Activity-Rest Patterns and Symptoms in Inflammatory Bowel DiseaseConley S, Jeon S, Lehner V, Proctor D, Redeker N. 0636 Activity-Rest Patterns and Symptoms in Inflammatory Bowel Disease. Sleep 2019, 42: a253-a253. DOI: 10.1093/sleep/zsz067.634.
• Physicians and Scientists in Gastroenterology as Legislative Advocates: Practical Tips and Resources.Kupfer SS, Siddique SM, Proctor DD. Physicians and Scientists in Gastroenterology as Legislative Advocates: Practical Tips and Resources. Gastroenterology 2019, 156: 834-837. PMID: 30772344, PMCID: PMC6685313, DOI: 10.1053/j.gastro.2018.10.058.
• How to Get Involved in Global Health.Proctor DD. How to Get Involved in Global Health. Gastroenterology 2019, 156: 542-544. PMID: 30641055, DOI: 10.1053/j.gastro.2019.01.012.
• Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel DiseaseConley S, Jeon S, Proctor DD, Sandler RS, Redeker NS. Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel Disease. Journal Of Nursing Scholarship 2018, 50: 473-481. PMID: 29971936, PMCID: PMC6120775, DOI: 10.1111/jnu.12409.
• Evolution of Intrahepatic Shunts in a Patient With Hereditary Hemorrhagic Telangiectasia.Haghighat L, Brandt EJ, Proctor DD, Garcia-Tsao G, Pollak J, Young L. Evolution of Intrahepatic Shunts in a Patient With Hereditary Hemorrhagic Telangiectasia. Annals Of Internal Medicine 2018, 169: 508-509. PMID: 29868721, DOI: 10.7326/l18-0036.
• THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIABrandt E, Haghighat L, Garcia-Tsao G, Henderson K, Pollak J, Proctor D, Young L. THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA. Journal Of The American College Of Cardiology 2018, 71: a2393. DOI: 10.1016/s0735-1097(18)32934-6.
• Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National SurveyNguyen VQ, Mays JL, Lang M, Wu Y, Dassopoulos T, Regueiro M, Moss A, Proctor DD, Sorrentino D. Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National Survey. Digestive Diseases And Sciences 2017, 63: 53-60. PMID: 29147878, DOI: 10.1007/s10620-017-4844-z.
• Symptom clusters in adults with inflammatory bowel diseaseConley S, Proctor DD, Jeon S, Sandler RS, Redeker NS. Symptom clusters in adults with inflammatory bowel disease. Research In Nursing & Health 2017, 40: 424-434. PMID: 28833284, PMCID: PMC5597486, DOI: 10.1002/nur.21813.
• JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in MacrophagesHedl M, Proctor DD, Abraham C. JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages. The Journal Of Immunology 2016, 197: 3695-3704. PMID: 27664279, PMCID: PMC5127452, DOI: 10.4049/jimmunol.1600845.
• Global Health Education in Gastroenterology Fellowship: A National SurveyJirapinyo P, Hunt RS, Tabak YP, Proctor DD, Makrauer FL. Global Health Education in Gastroenterology Fellowship: A National Survey. Digestive Diseases And Sciences 2016, 61: 3443-3450. PMID: 27796765, DOI: 10.1007/s10620-016-4308-x.
• A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome CompositionLi D, Achkar JP, Haritunians T, Jacobs JP, Hui KY, D'Amato M, Brand S, Radford-Smith G, Halfvarson J, Niess JH, Kugathasan S, Büning C, Schumm LP, Klei L, Ananthakrishnan A, Aumais G, Baidoo L, Dubinsky M, Fiocchi C, Glas J, Milgrom R, Proctor DD, Regueiro M, Simms LA, Stempak JM, Targan SR, Törkvist L, Sharma Y, Devlin B, Borneman J, Hakonarson H, Xavier RJ, Daly M, Brant SR, Rioux JD, Silverberg MS, Cho JH, Braun J, McGovern DP, Duerr RH. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition. Gastroenterology 2016, 151: 724-732. PMID: 27492617, PMCID: PMC5037008, DOI: 10.1053/j.gastro.2016.06.051.
• Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysisParian A, Limketkai B, Koh J, Brant SR, Bitton A, Cho JH, Duerr RH, McGovern DP, Proctor DD, Regueiro MD, Rioux JD, Schumm P, Taylor KD, Silverberg MS, Steinhart AH, Hernaez R, Lazarev M. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut 2016, 66: 1390. PMID: 27196594, PMCID: PMC5065377, DOI: 10.1136/gutjnl-2016-311550.
• Bernasko N, Proctor D. Invited commentary. Characteristics and Behavior of Elderly-Onset Inflammatory Bowel Disease: A Multi-Center US Study. PracticeUpdate website. Available at: http://www.practiceupdate.com/content/characteristics-and-behavior-of-elderly-onset-inflammatory-bowel-disease/43340/65/9/1. Accessed September 08, 2016. Bernasko N, Proctor D. Invited commentary. Characteristics and Behavior of Elderly-Onset Inflammatory Bowel Disease: A Multi-Center US Study. PracticeUpdate website. Available at: http://www.practiceupdate.com/content/characteristics-and-behavior-of-elderly-onset-inflammatory-bowel-disease/43340/65/9/1. Accessed September 08, 2016.
• Introduction to the “Fellows and Young GIs Section”To U, Proctor D. Introduction to the “Fellows and Young GIs Section”. Digestive Diseases And Sciences 2015, 61: 354-354. PMID: 26685909, DOI: 10.1007/s10620-015-3995-z.
• Tu1112 Global Health Curriculum in Gastroenterology Fellowship: A National SurveyJirapinyo P, Tabak Y, Hunt R, Proctor D, Makrauer F. Tu1112 Global Health Curriculum in Gastroenterology Fellowship: A National Survey. Gastroenterology 2015, 148: s-791. DOI: 10.1016/s0016-5085(15)32700-1.
• Erratum: EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional ImagingFaubion W, Fletcher J, O'Byrne S, Feagan B, de Villiers W, Salzberg B, Plevy S, Proctor D, Valentine J, Higgins P, Harris J, Diehl L, Wright L, Tew G, Luca D, Basu K, Keir M. Erratum: EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. The American Journal Of Gastroenterology 2014, 109: 780. DOI: 10.1038/ajg.2014.69.
• EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional ImagingFaubion WA, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. The American Journal Of Gastroenterology 2013, 108: 1891. PMID: 24126633, DOI: 10.1038/ajg.2013.354.
• The Influence of Depression on Quality of Life in Patients with Inflammatory Bowel DiseaseZhang CK, Hewett J, Hemming J, Grant T, Zhao H, Abraham C, Oikonomou I, Kanakia M, Cho JH, Proctor DD. The Influence of Depression on Quality of Life in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2013, 19: 1732-1739. PMID: 23669400, PMCID: PMC4623582, DOI: 10.1097/mib.0b013e318281f395.
• 565 Appendectomy and Extensive Disease Are Independent Predictors of Colectomy in Ulcerative Colitis: Results From a Large Cross-Sectional CohortParian A, Limketkai B, Koh J, Brant S, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm L, Taylor K, Silverberg M, Steinhart A, Lazarev M. 565 Appendectomy and Extensive Disease Are Independent Predictors of Colectomy in Ulcerative Colitis: Results From a Large Cross-Sectional Cohort. Gastroenterology 2013, 144: s-105. DOI: 10.1016/s0016-5085(13)60385-6.
• Mo1241 Patterns of Extraintestinal Manifestations in Ulcerative Colitis and Crohn's Disease: Results From a Large Cross-Sectional CohortKoh J, Limketkai B, Parian A, Brant S, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm L, Taylor K, Silverberg M, Steinhart A, Lazarev M. Mo1241 Patterns of Extraintestinal Manifestations in Ulcerative Colitis and Crohn's Disease: Results From a Large Cross-Sectional Cohort. Gastroenterology 2013, 144: s-615. DOI: 10.1016/s0016-5085(13)62274-x.
• Relationship Between Proximal Crohn's Disease Location and Disease Behavior and Surgery: A Cross-Sectional Study of the IBD Genetics ConsortiumLazarev M, Huang C, Bitton A, Cho JH, Duerr RH, McGovern DP, Proctor DD, Regueiro M, Rioux JD, Schumm PP, Taylor KD, Silverberg MS, Steinhart AH, Hutfless S, Brant SR. Relationship Between Proximal Crohn's Disease Location and Disease Behavior and Surgery: A Cross-Sectional Study of the IBD Genetics Consortium. The American Journal Of Gastroenterology 2012, 108: 106. PMID: 23229423, PMCID: PMC4059598, DOI: 10.1038/ajg.2012.389.
• Sa1248 Late Adult-Onset Inflammatory Bowel Disease Patients Require Surgery Earlier During Their Disease Course Compared to Early Adult-Onset PatientsHa C, Bayless T, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm L, Taylor K, Silverberg M, Steinhart A, Brant S. Sa1248 Late Adult-Onset Inflammatory Bowel Disease Patients Require Surgery Earlier During Their Disease Course Compared to Early Adult-Onset Patients. Gastroenterology 2012, 142: s-253-s-254. DOI: 10.1016/s0016-5085(12)60955-x.
• Mo1680 Assessing Crohn's Disease Inflammatory Biomarker Diagnostic Accuracy Using Ileocolonoscopy or a Combined Ileocolonoscopy-CTE Score in the Embark StudyFaubion W, Fletcher J, de Villiers W, Salzberg B, Plevy S, Proctor D, Valentine J, Feagan B, Higgins P, Harris J, Luca D, O'Byrne S, Keir M. Mo1680 Assessing Crohn's Disease Inflammatory Biomarker Diagnostic Accuracy Using Ileocolonoscopy or a Combined Ileocolonoscopy-CTE Score in the Embark Study. Gastroenterology 2012, 142: s-658. DOI: 10.1016/s0016-5085(12)62535-9.
• The Process of Applying for Gastroenterology FellowshipDeCross AJ, Proctor DD. The Process of Applying for Gastroenterology Fellowship. Gastroenterology 2012, 142: 1405-1408. PMID: 22542457, DOI: 10.1053/j.gastro.2012.04.040.
• A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility LociKenny EE, Pe'er I, Karban A, Ozelius L, Mitchell AA, Ng SM, Erazo M, Ostrer H, Abraham C, Abreu MT, Atzmon G, Barzilai N, Brant SR, Bressman S, Burns ER, Chowers Y, Clark LN, Darvasi A, Doheny D, Duerr RH, Eliakim R, Giladi N, Gregersen PK, Hakonarson H, Jones MR, Marder K, McGovern DP, Mulle J, Orr-Urtreger A, Proctor DD, Pulver A, Rotter JI, Silverberg MS, Ullman T, Warren ST, Waterman M, Zhang W, Bergman A, Mayer L, Katz S, Desnick RJ, Cho JH, Peter I. A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility Loci. PLOS Genetics 2012, 8: e1002559. PMID: 22412388, PMCID: PMC3297573, DOI: 10.1371/journal.pgen.1002559.
• Prospective Evaluation of Acute Graft-Versus-Host DiseaseAslanian H, Chander B, Robert M, Cooper D, Proctor D, Seropian S, Jain D. Prospective Evaluation of Acute Graft-Versus-Host Disease. Digestive Diseases And Sciences 2011, 57: 720-725. PMID: 22011927, DOI: 10.1007/s10620-011-1938-x.
• Littoral cell angioma of the spleen diagnosed by endoscopic ultrasound‐guided fine‐needle aspiration biopsyNagarajan P, Cai G, Padda MS, Selbst M, Kowalski D, Proctor DD, Chhieng D, Aslanian HR, Harigopal M. Littoral cell angioma of the spleen diagnosed by endoscopic ultrasound‐guided fine‐needle aspiration biopsy. Diagnostic Cytopathology 2011, 39: 318-322. PMID: 21488173, DOI: 10.1002/dc.21384.
• Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panés J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics 2011, 43: 246-52. PMID: 21297633, PMCID: PMC3084597, DOI: 10.1038/ng.764.
• Getting to the Core of the Women’s Curriculum—It’s Time to Change the Way We Train Our FellowsProctor DD. Getting to the Core of the Women’s Curriculum—It’s Time to Change the Way We Train Our Fellows. Digestive Diseases And Sciences 2011, 56: 626-628. PMID: 21253832, DOI: 10.1007/s10620-011-1577-2.
• The Match: Five Years LaterProctor DD, Decross AJ, Willis CE, Jones TN, Pardi DS. The Match: Five Years Later. Gastroenterology 2010, 140: 15-18. PMID: 21095249, DOI: 10.1053/j.gastro.2010.11.009.
• Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility lociFranke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics 2010, 42: 1118-1125. PMID: 21102463, PMCID: PMC3299551, DOI: 10.1038/ng.717.
• Report of the AGA Institute Education and Training Committee Task Force on Physician ReentryDecross AJ, Pardi DS, Proctor DD. Report of the AGA Institute Education and Training Committee Task Force on Physician Reentry. Gastroenterology 2010, 139: e17-e26. PMID: 20800161, DOI: 10.1053/j.gastro.2010.06.012.
• 760 Divergence in L4 Crohn's Disease: Jejunal, Not Esophagogastroduodenal Involvement, is Protective of L2 Disease Location, and a Risk for Stricturing Behavior and Multiple Abdominal Surgeries. Report From the NIDDK-IBDGC RegistryLazarev M, Hutfless S, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm P, Taylor K, Silverberg M, Steinhart H, Brant S. 760 Divergence in L4 Crohn's Disease: Jejunal, Not Esophagogastroduodenal Involvement, is Protective of L2 Disease Location, and a Risk for Stricturing Behavior and Multiple Abdominal Surgeries. Report From the NIDDK-IBDGC Registry. Gastroenterology 2010, 138: s-105. DOI: 10.1016/s0016-5085(10)60481-7.
• Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trialWright MJ, Sullivan RR, Gaffney‐Stomberg E, Caseria DM, O'Brien KO, Proctor DD, Simpson CA, Kerstetter JE, Insogna KL. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trial. Journal Of Bone And Mineral Research 2010, 25: 2205-2211. PMID: 20499372, PMCID: PMC3312746, DOI: 10.1002/jbmr.108.
• ChemInform Abstract: Spectrum of Histologic Changes in Colonic Biopsies in Patients Treated with Mycophenolate MofetilSelbst M, Ahrens W, Robert M, Friedman A, Proctor D, Jain D. ChemInform Abstract: Spectrum of Histologic Changes in Colonic Biopsies in Patients Treated with Mycophenolate Mofetil. ChemInform 2010, 41: no-no. DOI: 10.1002/chin.201010274.
• International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasiaFaughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. Journal Of Medical Genetics 2009, 48: 73. PMID: 19553198, DOI: 10.1136/jmg.2009.069013.
• Phenotypic and Genotypic Characteristics of Inflammatory Bowel Disease in French Canadians: Comparison With a Large North American RepositoryElkadri A, Bitton A, Cohen A, Griffiths A, Deslandres C, Proctor D, McGovern D, Langelier D, Bernard E, Torres E, Wild G, Nguyen G, Jobin G, Aumais G, Steinhart H, Rioux J, Cho J, Bhat M, Silverberg M, Regueiro M, Goyette P, Pare P, Lahaie R, Duerr R, Brant S, Dassopoulos T. Phenotypic and Genotypic Characteristics of Inflammatory Bowel Disease in French Canadians: Comparison With a Large North American Repository. The American Journal Of Gastroenterology 2009, 104: 2233. PMID: 19513023, PMCID: PMC2742627, DOI: 10.1038/ajg.2009.267.
• Response to the Institute of Medicine’s recommendations on resident duty hours: the medical residency program and GI fellowship viewpoints.Katzka DA, Proctor DD. Response to the Institute of Medicine’s recommendations on resident duty hours: the medical residency program and GI fellowship viewpoints. Gastroenterology 2009;136(4):1147-1148.
• The GI fellowship viewpoint.Katzka DA, Proctor DD. The GI fellowship viewpoint. Gastroenterology 2009, 136: 1147-8. PMID: 19233332, DOI: 10.1053/j.gastro.2009.02.017.
• Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetilSelbst MK, Ahrens WA, Robert ME, Friedman A, Proctor DD, Jain D. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Modern Pathology 2009, 22: 737-743. PMID: 19329937, DOI: 10.1038/modpathol.2009.44.
• Ulcerative colitis–risk loci on chromosomes 1p36 and 12q15 found by genome-wide association studySilverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, Achkar JP, Goyette P, Scott R, Xu W, Barmada MM, Klei L, Daly MJ, Abraham C, Bayless TM, Bossa F, Griffiths AM, Ippoliti AF, Lahaie RG, Latiano A, Paré P, Proctor DD, Regueiro MD, Steinhart AH, Targan SR, Schumm LP, Kistner EO, Lee AT, Gregersen PK, Rotter JI, Brant SR, Taylor KD, Roeder K, Duerr RH. Ulcerative colitis–risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nature Genetics 2009, 41: 216-220. PMID: 19122664, PMCID: PMC2652837, DOI: 10.1038/ng.275.
• The Gastroenterology Fellowship Match—The First Two YearsNiederle M, Proctor DD, Roth AE. The Gastroenterology Fellowship Match—The First Two Years. Gastroenterology 2008, 135: 344-346. PMID: 18619966, DOI: 10.1053/j.gastro.2008.06.075.
• Hormonal Therapy for the Treatment of Gastrointestinal Bleeding in Hereditary Hemorrhagic TelangiectasiaProctor DD, Henderson KJ, Dziura JD, White RI. Hormonal Therapy for the Treatment of Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia. Journal Of Clinical Gastroenterology 2008, 42: 756-757. PMID: 18496387, DOI: 10.1097/mcg.0b013e318032391f.
• Utilization of and Adherence to the Gastroenterology Core Curriculum on Hepatology Training During a Gastrointestinal FellowshipGuardino JM, Proctor DD, Lopez R, Carey W. Utilization of and Adherence to the Gastroenterology Core Curriculum on Hepatology Training During a Gastrointestinal Fellowship. Clinical Gastroenterology And Hepatology 2008, 6: 682-688.e2. PMID: 18356116, DOI: 10.1016/j.cgh.2007.12.038.
• Proton pump‐inhibiting drugs, calcium homeostasis, and bone healthWright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump‐inhibiting drugs, calcium homeostasis, and bone health. Nutrition Reviews 2008, 66: 103-108. PMID: 18254877, DOI: 10.1111/j.1753-4887.2008.00015.x.
• Relation Between Medicare Screening Reimbursement and Stage at Diagnosis for Older Patients With Colon CancerGross CP, Andersen MS, Krumholz HM, McAvay GJ, Proctor D, Tinetti ME. Relation Between Medicare Screening Reimbursement and Stage at Diagnosis for Older Patients With Colon Cancer. JAMA 2006, 296: 2815-2822. PMID: 17179458, DOI: 10.1001/jama.296.23.2815.
• What Will Be Needed for the New Gastroenterology Fellowship Match to Succeed?Niederle M, Proctor DD, Roth AE. What Will Be Needed for the New Gastroenterology Fellowship Match to Succeed? Gastroenterology 2006, 130: 218-224. PMID: 16401484, DOI: 10.1053/j.gastro.2005.10.058.
• American gastroenterological association future trends committee report: effects of aging of the population on gastroenterology practice, education, and research.Hall KE, Proctor DD, Fisher L, Rose S. American gastroenterological association future trends committee report: effects of aging of the population on gastroenterology practice, education, and research. Gastroenterology 2005, 129: 1305-38. PMID: 16230084, DOI: 10.1053/j.gastro.2005.06.013.
• Gastroenterology fellowship programs rejoin the match.Proctor DD. Gastroenterology fellowship programs rejoin the match. Gastroenterology 2005, 129: 780-1. PMID: 16143113, DOI: 10.1053/j.gastro.2005.07.049.
• Enteroscopic Evaluation of the Gastrointestinal Tract in Symptomatic Patients With Hereditary Hemorrhagic TelangiectasiaProctor DD, Henderson KJ, Dziura JD, Longacre AV, White RI. Enteroscopic Evaluation of the Gastrointestinal Tract in Symptomatic Patients With Hereditary Hemorrhagic Telangiectasia. Journal Of Clinical Gastroenterology 2005, 39: 115-119. PMID: 15681905, DOI: 10.1097/01.mcg.0000150193.15978.f9.
• The Clinical and Pathologic Significance of Microscopic ColitisProctor D. The Clinical and Pathologic Significance of Microscopic Colitis. Journal Of Clinical Gastroenterology 2004, 38: s31. PMID: 15115927, DOI: 10.1097/01.mcg.0000127687.94090.04.
• Critical issues in digestive diseasesProctor DD. Critical issues in digestive diseases. Clinics In Chest Medicine 2003, 24: 623-632. PMID: 14710694, DOI: 10.1016/s0272-5231(03)00103-5.
• Does Treatment of Inflammatory Bowel Disease Prevent Cancer?West B, Proctor D, Itzkowitz S, Loftus E, Nair P. Does Treatment of Inflammatory Bowel Disease Prevent Cancer? Journal Of Clinical Gastroenterology 2003, 36: s94-s96. DOI: 10.1097/00004836-200305001-00016.
• Role of Interstitial Cells of Cajal in Motility Disorders of the BowelJain D, Moussa K, Tandon M, Culpepper-Morgan J, Proctor DD. Role of Interstitial Cells of Cajal in Motility Disorders of the Bowel. The American Journal Of Gastroenterology 2003, 98: ajg2003146. PMID: 12650797, DOI: 10.1111/j.1572-0241.2003.07295.x.
• Diagnosis and Management of Gastrointestinal Bleeding in Patients With Hereditary Hemorrhagic TelangiectasiaLongacre AV, Gross CP, Proctor D, Henderson KJ, Gallitelli M, White R. Diagnosis and Management of Gastrointestinal Bleeding in Patients With Hereditary Hemorrhagic Telangiectasia. The American Journal Of Gastroenterology 2003, 98: 59. PMID: 12526937, DOI: 10.1111/j.1572-0241.2003.07185.x.
• Absence of c-kit + cells in resected segments of patients with chronic intestinal pseudo-obstruction (CIIP)Moussa K, Proctor D, Jain D, Culpepper-Morgan J. Absence of c-kit + cells in resected segments of patients with chronic intestinal pseudo-obstruction (CIIP). Gastroenterology 2000, 118: a866. DOI: 10.1016/s0016-5085(00)85606-1.
• Missionary work – it’s about more than doing endoscopies.Proctor DD. Missionary work – it’s about more than doing endoscopies. AGA Perspectives 2013;9(3):22-23.
• Rockey DC, Harrison SA, Wong RKH, Schiller LR, Proctor DD, Wolfe MM, Chutkan R, Vargo JJ, Waxler A. The gastroenterology core curriculum, third edition – May 2007. Gastroenterology 2007132(5):2012-2018. Rockey DC, Harrison SA, Wong RKH, Schiller LR, Proctor DD, Wolfe MM, Chutkan R, Vargo JJ, Waxler A. The gastroenterology core curriculum, third edition – May 2007. Gastroenterology 2007132(5):2012-2018.